231 related articles for article (PubMed ID: 31659558)
1. Fabrication of Ibrutinib Nanosuspension by Quality by Design Approach: Intended for Enhanced Oral Bioavailability and Diminished Fast Fed Variability.
Rangaraj N; Pailla SR; Chowta P; Sampathi S
AAPS PharmSciTech; 2019 Oct; 20(8):326. PubMed ID: 31659558
[TBL] [Abstract][Full Text] [Related]
2. Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology.
Gajera BY; Shah DA; Dave RH
Int J Pharm; 2019 Mar; 559():348-359. PubMed ID: 30721724
[TBL] [Abstract][Full Text] [Related]
3. Etoposide Amorphous Nanopowder for Improved Oral Bioavailability: Formulation Development, Optimization, in vitro and in vivo Evaluation.
Wang Y; Wang S; Xu Y; Wang P; Li S; Liu L; Liu M; Jin X
Int J Nanomedicine; 2020; 15():7601-7613. PubMed ID: 33116490
[TBL] [Abstract][Full Text] [Related]
4. Fabrication and characterization of glimepiride nanosuspension by ultrasonication-assisted precipitation for improvement of oral bioavailability and in vitro α-glucosidase inhibition.
Rahim H; Sadiq A; Khan S; Amin F; Ullah R; Shahat AA; Mahmood HM
Int J Nanomedicine; 2019; 14():6287-6296. PubMed ID: 31496686
[TBL] [Abstract][Full Text] [Related]
5. Enhanced Solubility and Dissolution Rate of Lacidipine Nanosuspension: Formulation Via Antisolvent Sonoprecipitation Technique and Optimization Using Box-Behnken Design.
Kassem MAA; ElMeshad AN; Fares AR
AAPS PharmSciTech; 2017 May; 18(4):983-996. PubMed ID: 27506564
[TBL] [Abstract][Full Text] [Related]
6. Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability.
Jain S; Reddy VA; Arora S; Patel K
Drug Deliv Transl Res; 2016 Oct; 6(5):498-510. PubMed ID: 27129488
[TBL] [Abstract][Full Text] [Related]
7. Comparative study on stabilizing ability of food protein, non-ionic surfactant and anionic surfactant on BCS type II drug carvedilol loaded nanosuspension: Physicochemical and pharmacokinetic investigation.
Geng T; Banerjee P; Lu Z; Zoghbi A; Li T; Wang B
Eur J Pharm Sci; 2017 Nov; 109():200-208. PubMed ID: 28811130
[TBL] [Abstract][Full Text] [Related]
8. Formulation and Evaluation of Naringenin Nanosuspensions for Bioavailability Enhancement.
Gera S; Talluri S; Rangaraj N; Sampathi S
AAPS PharmSciTech; 2017 Nov; 18(8):3151-3162. PubMed ID: 28534300
[TBL] [Abstract][Full Text] [Related]
9. Fabrication of Nanosuspension Directly Loaded Fast-Dissolving Films for Enhanced Oral Bioavailability of Olmesartan Medoxomil: In Vitro Characterization and Pharmacokinetic Evaluation in Healthy Human Volunteers.
Alsofany JM; Hamza MY; Abdelbary AA
AAPS PharmSciTech; 2018 Jul; 19(5):2118-2132. PubMed ID: 29700766
[TBL] [Abstract][Full Text] [Related]
10. Rutin nanosuspension for potential management of osteoporosis: effect of particle size reduction on oral bioavailability,
Gera S; Pooladanda V; Godugu C; Swamy Challa V; Wankar J; Dodoala S; Sampathi S
Pharm Dev Technol; 2020 Oct; 25(8):971-988. PubMed ID: 32403972
[TBL] [Abstract][Full Text] [Related]
11. A quality-by-design study to develop Nifedipine nanosuspension: examining the relative impact of formulation variables, wet media milling process parameters and excipient variability on drug product quality attributes.
Patel PJ; Gajera BY; Dave RH
Drug Dev Ind Pharm; 2018 Dec; 44(12):1942-1952. PubMed ID: 30027778
[TBL] [Abstract][Full Text] [Related]
12. Nanosizing of valsartan by high pressure homogenization to produce dissolution enhanced nanosuspension: pharmacokinetics and pharmacodyanamic study.
Gora S; Mustafa G; Sahni JK; Ali J; Baboota S
Drug Deliv; 2016; 23(3):940-50. PubMed ID: 24937379
[TBL] [Abstract][Full Text] [Related]
13. Formulation, optimization and in vitro-in vivo evaluation of febuxostat nanosuspension.
Ahuja BK; Jena SK; Paidi SK; Bagri S; Suresh S
Int J Pharm; 2015 Jan; 478(2):540-52. PubMed ID: 25490182
[TBL] [Abstract][Full Text] [Related]
14. Enhanced biopharmaceutical performance of brick dust molecule nilotinib via stabilized amorphous nanosuspension using a facile acid-base neutralization approach.
Chougule M; Sirvi A; Saini V; Kashyap M; Sangamwar AT
Drug Deliv Transl Res; 2023 Oct; 13(10):2503-2519. PubMed ID: 37024611
[TBL] [Abstract][Full Text] [Related]
15. [Preparation and characterization of icariin nanosuspension and lyophilized powder].
Hui-Rong XI; Hui-Ping MA; Ke-Ming C; Xiao-Shuan L
Zhongguo Zhong Yao Za Zhi; 2020 Oct; 45(20):4902-4908. PubMed ID: 33350263
[TBL] [Abstract][Full Text] [Related]
16. Exploitation of nanocrystal suspension as an effective oral formulation for oxfendazole.
Sun Y; Chen D; Zhao Y; Zhou K; Zhang B; Wang H; Xie S
Drug Deliv Transl Res; 2022 May; 12(5):1219-1229. PubMed ID: 34148210
[TBL] [Abstract][Full Text] [Related]
17. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.
Sawant KK; Patel MH; Patel K
Drug Dev Ind Pharm; 2016; 42(5):758-68. PubMed ID: 26548349
[TBL] [Abstract][Full Text] [Related]
18. Physicochemical, Pharmacodynamic and Pharmacokinetic Characterization of Soluplus Stabilized Nanosuspension of Tacrolimus.
Varshosaz J; Minayian M; Yazdekhasti S
Curr Drug Deliv; 2017; 14(4):521-535. PubMed ID: 27697037
[TBL] [Abstract][Full Text] [Related]
19. Fabrication of carvedilol nanosuspensions through the anti-solvent precipitation-ultrasonication method for the improvement of dissolution rate and oral bioavailability.
Liu D; Xu H; Tian B; Yuan K; Pan H; Ma S; Yang X; Pan W
AAPS PharmSciTech; 2012 Mar; 13(1):295-304. PubMed ID: 22246736
[TBL] [Abstract][Full Text] [Related]
20. Lipid nanoparticles of zaleplon for improved oral delivery by Box-Behnken design: optimization, in vitro and in vivo evaluation.
Dudhipala N; Janga KY
Drug Dev Ind Pharm; 2017 Jul; 43(7):1205-1214. PubMed ID: 28274147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
